1694 SIDE EFFECTS OF BCG IN THE TREATMENT OF INTERMEDIATE AND HIGH RISK TA T1 PAPILLARY CARCINOMA OF THE BLADDER: RESULTS FROM EORTC GU CANCERS GROUP RANDOMIZED STUDY 30962 COMPARING 1/3 DOSE VS FULL DOSE DURING 1 OR 3 YEARS

708 Side effects of BCG in the treatment of intermediate and high risk Ta T1 papillary carcinoma of the bladder: Results from EORTC GU Cancers Group randomized study 30962 comparing 1/3 dose vs full dose during 1 or 3 years

European Urology Supplements ◽

10.1016/s1569-9056(13)61190-2 ◽

2013 ◽

Vol 12 (1) ◽

pp. e708

Author(s):

M. Brausi ◽

J. Oddens ◽

R. Sylvester ◽

S. Colette ◽

P. Gontero ◽

...

Keyword(s):

Side Effects ◽

High Risk ◽

Papillary Carcinoma ◽

Randomized Study ◽

Full Dose ◽

Re: Side Effects of bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-Risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-Third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG

The Journal of Urology ◽

10.1016/j.juro.2014.09.034 ◽

2014 ◽

Vol 192 (6) ◽

pp. 1641-1641

Author(s):

David P. Wood

Keyword(s):

Side Effects ◽

High Risk ◽

Papillary Carcinoma ◽

Phase 3 ◽

Full Dose ◽

Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG

European Urology ◽

10.1016/j.eururo.2013.07.021 ◽

2014 ◽

Vol 65 (1) ◽

pp. 69-76 ◽

Cited By ~ 122

Author(s):

Maurizio Brausi ◽

Jorg Oddens ◽

Richard Sylvester ◽

Aldo Bono ◽

Cees van de Beek ◽

...

Keyword(s):

Side Effects ◽

High Risk ◽

Papillary Carcinoma ◽

Phase 3 ◽

Full Dose ◽

Faculty Opinions recommendation of Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717964808.793498086 ◽

2014 ◽

Author(s):

Alexander Bachmann ◽

Jan Ebbing

Keyword(s):

High Risk ◽

Urinary Bladder ◽

Papillary Carcinoma ◽

Randomized Study ◽

Faculty Opinions recommendation of Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717964808.793466279 ◽

2012 ◽

Author(s):

Mark Gonzalgo

Keyword(s):

High Risk ◽

Urinary Bladder ◽

Papillary Carcinoma ◽

Randomized Study ◽

Faculty Opinions recommendation of Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717964808.793475577 ◽

2013 ◽

Author(s):

Evangelos Liatsikos ◽

Panagiotis Kallidonis

Keyword(s):

High Risk ◽

Urinary Bladder ◽

Papillary Carcinoma ◽

Randomized Study ◽

Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance

European Urology ◽

10.1016/j.eururo.2012.10.039 ◽

2013 ◽

Vol 63 (3) ◽

pp. 462-472 ◽

Cited By ~ 221

Author(s):

Jorg Oddens ◽

Maurizio Brausi ◽

Richard Sylvester ◽

Aldo Bono ◽

Cees van de Beek ◽

...

Keyword(s):

High Risk ◽

Urinary Bladder ◽

Papillary Carcinoma ◽

Randomized Study ◽

Re: Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance

European Urology ◽

10.1016/j.eururo.2013.04.027 ◽

2013 ◽

Vol 64 (1) ◽

pp. 171-172

Author(s):

Brant A. Inman

Keyword(s):

High Risk ◽

Urinary Bladder ◽

Papillary Carcinoma ◽

Randomized Study ◽

Re: Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance

European Urology ◽

10.1016/j.eururo.2013.12.034 ◽

2014 ◽

Vol 65 (4) ◽

pp. 847-848 ◽

Cited By ~ 2

Author(s):

Eduardo Solsona

Keyword(s):

High Risk ◽

Urinary Bladder ◽

Papillary Carcinoma ◽

Randomized Study ◽

Re: Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-Risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-Third Dose versus Full Dose and 1 Year versus 3 Years of Maintenance

The Journal of Urology ◽

10.1016/j.juro.2013.10.133 ◽

2014 ◽

Vol 191 (2) ◽

pp. 348-349

Author(s):

David P. Wood

Keyword(s):

High Risk ◽

Urinary Bladder ◽

Papillary Carcinoma ◽

Randomized Study ◽